



RealRate

PHARMACEUTICAL 2021











PHARMACEUTICAL 2021

MARIZYME INC. Rank 14 of 402



The relative strengths and weaknesses of MARIZYME INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 283% points. The greatest weakness of MARIZYME INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 295%, being 247% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	3,106
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	721
Liabilities, Non-Current	1,075
Other Assets	43,970
Other Compr. Net Income	0
Other Expenses	5,997
Other Liabilities	0
Other Net Income	-45
Other Revenues	197
Property and Equipment	7.1
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	47,084
Liabilities	1,796
Expenses	5,997
Revenues	197
Stockholders Equity	45,288
Net Income	-5,845
Comprehensive Net Income	-5,845
Economic Capital Ratio	295%

